{
    "medicine_id": "01cb131df215034d7cad65e95b78d10037bf9113",
    "platform_id": "DB06137",
    "metadata": {
        "name": "Klisyri 10 mg 1g Ointment",
        "composition": "10 mg 1g Tirbanibulin",
        "clinical_particulars": {
            "therapeutic_indications": "Tirbanibulin is indicated for the topical treatment of actinic keratosis on the face or scalp L27786",
            "contraindications": {
                "disease": "The LD sub 50 sub value of tirbanibulin has not been determined While there is limited information on overdose from tirbanibulin it may lead to an increase in the incidence and severity of local skin reactions L27786",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "In clinical trials composed comprising patients with actinic keratosis of the face or scalp tirbanibulin promoted complete clearance of actinic keratosis lesions at day 57 in treated areas in 44 54 of patients compared to 5 13 of patients who received the placebo L27786 Actinic keratosis is a chronic pre malignant condition characterized by lesions and proliferation of neoplastic keratinocytes A225721 Tirbanibulin mediates an anti proliferative effect by inhibiting tubulin polymerization and Src kinase signalling A225711 Tirbanibulin inhibited primary tumour growth and metastasis in many preclinical animal models of cancer A225716 A225726 A225731 A225736 In human triple negative breast cancer or estrogen receptor ER progesterone receptor PR human epidermal growth factor receptor 2 HER2 negative tumour xenografts tirbanibulin suppressed tumour growth and metastasis A225726 Tirbanibulin was also shown to restore functional ER\u03b1 expression in ER\u03b1 negative breast tumours A225796 Tirbanibulin promoted synergistic tumour growth inhibition of breast cancer cell lines when used in combination with tamoxifen A225731 A225796 and paclitaxel A225726 In a clinical trial comprising patients with advanced solid tumours dose limiting toxicities of tirbanibulin included elevated liver transaminases neutropenia and fatigue A225736",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}